Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Targeting Vps34 makes melanoma and CRC eligible to anti–PD-1/PD-L1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse CRC model, the autophagy inhibitors, such as SB02024 and SAR405, increased NK and T cell infiltration in TME and reversed resistance to anti-PD-1 or anti-PD-L1 [47].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“Supporting this finding, lysosomotropic agents or small molecules targeting the PtdIns3K PIK3C3/VSP34 have been efficiently combined with therapeutic regimens that promote the activation of the immune system against cancer cells (Janji et al, 2020; Noman et al, 2020).”
From Autophagy in major human diseases (2021) · cites this paper as Noman et al, 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“This statement is supported by clinical data showing that the presence of preexisting T cells close to the invasive tumor margin is a key determinant to achieving a long-lasting response to anti–PD-1 therapy in melanoma (4).”
Autophagy: Renovation of Cells and Tissues
Mizushima, N., & Komatsu, M. (2011) · Cell · doi:10.1016/j.cell.2011.10.026 · Cited by 6,418
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 5×
“INTRODUCTION Immune checkpoint inhibitors (ICIs), exemplified by antibodies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1), are groundbreaking treatment for many cancers, including melanoma (1).”
InfluentialChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206 · cited 1×
“CCL5, CXCL10, and IFN are all known to promote recruitment of cytotoxic T cells into the TME (18), and this is likely the explanation for why we observed enhanced recruitment of NK, CD8+ T, and CD4+ T effector cells into the tumor bed following Vps34 inhibition.”
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 1×
“We used melanoma B16F10, previously described as immune hot tumors but not responding to anti–PD-L1/PD-1 (21), and CRC CT26, reported as immune cold tumors and partially responding to anti–PD-L1/PD-1 (22).”
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498 · cited 1×
“While the impact of blocking autophagy on the inhibition of tumor growth has been well documented by several studies ( 7 , 8 , 14 , 23 – 26 ), the effect of targeting autophagy on the immune landscape of tumors is still only partially defined.”
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“In this regard, it is tempting to speculate that type I IFN signature could be responsible for triggering the release of more CCL5 and CXCL10 in the TME, as previously reported (37), to attract more NK and CD8+ T cells into the tumor bed.”
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000 · cited 1×
“The immune phenotyping of tumors combined with the cytokine network results reported in this study strongly predicts that the immune-supportive characteristic of Vps34itreated TME relies on the establishment of an inflamed TME supported by the presence of tumor-infiltrating lymphocytes, high levels of IFN-producing C…”
Cited by
Items 101–200 of 268
Firing up the cold tumors by targeting Vps34
Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1809936 · Cited by 30
“By using immunocompromised NOD SCID Gamma (NSG) mice or immunocompetent mice depleted for NK or CD8 cells, we demonstrated that both NK and CD8 T effector cells are the major immune cells controlling the growth of Vps34-targeted B16-F10 tumors.(9) We next evaluated the expression of several proinflammatory chemokines/…”
BackgroundMethodSelf-citationAlbadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 38
Targeting autophagy as a therapeutic strategy against pancreatic cancer
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01889-1 · Cited by 29
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors
Hu, D. X., Patel, S. D., Chen, H., Wang, S., Staben, S. T., Dimitrova, Y. N., Wallweber, H. A., Lee, J. Y., Chan, G. K. Y., Sneeringer, C. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01180 · Cited by 31
Zhang, L., Zhu, Y., Zhang, J., Zhang, L., & Chen, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.966012 · Cited by 32
“Additionally, inhibiting VPS34 induces the infiltration of NK, CD8, and CD4 T cells in melanoma and colorectal cancer (Noman et al., 2020).”
BackgroundMolecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion
Gan, L.-L., Hii, L., Wong, S. F., Leong, C., & Mai, C. (2020) · Cancers · doi:10.3390/cancers12071872 · Cited by 29
Anti-tumor immunity influences cancer cell reliance upon ATG7
Arensman, M. D., Yang, X. S., Zhong, W., Bisulco, S., Upeslacis, E., Rosfjord, E. C., Deng, S., Abraham, R. T., & Eng, C. H. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1800162 · Cited by 27
“Another recent study demonstrated that genetic or pharmacological inhibition of VPS34 enhanced anti-tumor immunity.(37) In sum, these results suggest that tumor-intrinsic autophagy alters immune visibility of tumors, although these data do not rule out a contribution for non-autophagic pathways.”
BackgroundInfluentialYang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03565-7 · Cited by 28
“[114] reported that VSP34 regulated the TME through its kinase activity, and VSP34 protein knockdown or VSP34 kinase activity inhibition could transform tumors from “cold tumors” to “hot tumors” to enhance the effect of ICIs.”
BackgroundBestion, E., Raymond, É., Mezouar, S., & Halfon, P. (2023) · Cells · doi:10.3390/cells12131702 · Cited by 27
“’s study revealed, using SB02024 or SAR405, a decrease in tumor growth and improved mice survival in melanoma and CRC tumors [60].”
BackgroundStapled Peptide Inhibitors of Autophagy Adapter LC3B
Cerulli, R. A., Shehaj, L., Brown, H., Pace, J. R., Mei, Y., & Kritzer, J. A. (2020) · ChemBioChem · doi:10.1002/cbic.202000212 · Cited by 26
Natural Killer Cells in Immunotherapy: Are We Nearly There?
Bachiller, M., Battram, A. M., Pérez-Amill, L., & Martín-Antonio, B. (2020) · Cancers · doi:10.3390/cancers12113139 · Cited by 27
“For example, pharmacological inhibition of Vps34, a kinase involved in autophagy, causes the microenvironment of melanoma and colorectal cancer tumors to become more pro-inflammatory, leading to enhanced recruitment of NK cells and other immune cells, and ultimately more effective anti-PD-1/PD-L1 therapy [143].”
BackgroundBypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Mortezaee, K., Majidpoor, J., Najafi, S., & Tasa, D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114150 · Cited by 27
Hashemi, M., Khosroshahi, E. M., Tanha, M., Khoushab, S., Bizhanpour, A., Azizi, F., Mohammadzadeh, M., Matinahmadi, A., Koohpar, Z. K., Asadi, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37376 · Cited by 26
“Once autophagy is pharmacologically or even genetically inhibited across multiple cancer cell species, it sensitizes them to immune-mediated eradication [154].”
BackgroundLv, D., Wu, X., Chen, X., Yang, S., Chen, W., Wang, M., Liu, Y., Gu, D., & Zeng, G. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02923-6 · Cited by 25
“In human PCa tumor specimens, insufficient immune cell infiltration is common, so PCa are considered as a cold tumor [55, 56].”
BackgroundAutophagy Paradox: Strategizing Treatment Modality in Melanoma
Pangilinan, C. R., Xu, X., Herlyn, M., & Liang, C. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01053-8 · Cited by 25
Budhwani, M., Turrell, G., Yu, M., Frazer, I. H., Mehdi, A. M., & Chandra, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.622643 · Cited by 29
“Targeting of the autophagy-related protein PIK3C3 (Vps34) has recently been demonstrated as a novel strategy to fire up “cold” tumors (Noman et al., 2020).”
BackgroundTargeting autophagy in colorectal cancer: An update on pharmacological small-molecule compounds
Li, Z., Si, W., Jin, W., Yuan, Z., Chen, Y., & Fu, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.011 · Cited by 24
Rinschen, M. M., Harder, J. L., Carter-Timofte, M. E., Rodriguez, L. Z., Mirabelli, C., Demir, F., Kurmasheva, N., Ramakrishnan, S. K., Kunke, M., Tan, Y., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abo7940 · Cited by 24
Giansanti, M., Theinert, T., Boeing, S. K., Haas, D., Schlegel, P., Vacca, P., Nazio, F., & Caruana, I. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01893-w · Cited by 27
“An intriguing reciprocal relationship also exists between autophagy inhibition and PD-L1 expression on cancer cells (e.g., gastric cancer, bladder cancer, melanoma), suggesting that targeting autophagy could sensitize tumors to ICIs combined treatments [162, 166–168].”
BackgroundInfluentialYalamandala, B. N., Chen, P.-H., Moorthy, T., Huynh, T. M. H., Chiang, W., & Hu, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030527 · Cited by 23
“In the literature, CQ effectively blocked autophagy at the lysosomal degradation step in mouse breast cancer cell lines, and targeting autophagy-inhibited melanoma tumor growth by inducing a massive infiltration of immune cells, including NK cells and CD8+ into B16-F10 tumor cells [43,44].”
BackgroundAddressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Ito, Y., Pan, D., Zhang, W., Zhang, X., Juan, T. Y., Pyrdol, J. W., Kyrysyuk, O., Doench, J. G., Liu, X. S., & Wucherpfennig, K. W. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1125 · Cited by 25
Zhang, Y., Zhang, Y., Li, J., Chen, L., Shi, K., Wang, S., Gao, X., Yan, B., Lyu, Y., Liu, X., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102226 · Cited by 23
Ding, D., Liang, R., Li, T., Lan, T., Li, Y., Huang, S., He, G., Ren, J., Li, W., Zheng, Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.052 · Cited by 24
Zhou, Z., Lei, J., Fang, J., Chen, P., Zhou, J., Wang, H., Sun, Z., Chen, Y., & Yin, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112637 · Cited by 28
Autophagy paradox: Genetic and epigenetic control of autophagy in cancer progression
Bhol, C. S., Senapati, P. K., Kar, R. K., Chew, G., Mahapatra, K. K., Lee, E. H. C., Kumar, A. P., Bhutia, S. K., & Sethi, G. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217909 · Cited by 24
The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1
Cai, J., & Yan, G. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.271 · Cited by 23
“71,72 The tight connection between autophagy and antitumor immunity suggests a rationale for the combination of autophagic inhibitors and oncolytic viruses.”
Kaczmarek, F., Marcinkowska‐Gapińska, A., Bartkowiak-Wieczorek, J., Nowak, M., Kmiecik, M., Brzezińska, K., Dotka, M., Brosz, P., Firlej, W., & Wojtyła-Buciora, P. (2025) · Cancers · doi:10.3390/cancers17122001 · Cited by 23
“Cold” colorectal cancer faces a bottleneck in immunotherapy
Liu, J., Yang, M., Bai, J., Liu, Z., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.240 · Cited by 23
Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence
Alhasan, B. A., Mikeladze, M. A., Guzhova, I. V., & Margulis, B. A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10085-3 · Cited by 22
Metabolic rewiring directs melanoma immunology
Sun, N., Tian, Y., Chen, Y., Guo, W., & Li, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909580 · Cited by 25
Donato, M. D., Giovannelli, P., Migliaccio, A., & Bilancio, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169008 · Cited by 22
“Furthermore, targeting Vps34 converts cold to hot inflamed tumours, increasing the efficacy of blocking PD-L1/PD-1 [49].”
BackgroundTumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer
Zuo, Y.-H., Gao, W., Xie, Y., Yang, S., Zhou, J.-T., Liang, H., & Fan, X. (2022) · BMC Medicine · doi:10.1186/s12916-022-02670-0 · Cited by 19
“Although tumor microenvironment (TME) restriction on immune cells has been well studied [6–8] and significant efforts have been taken to explore the potential way to enhance T cell infiltration into the tumor bed [9, 10], the mechanism of EGFR-mutation inducing un-inflamed TME remains unknown.”
BackgroundThe “Self-eating” of cancer-associated fibroblast: A potential target for cancer
Chen, Y., Zhang, X., Yang, H., Liang, T., & Bai, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114762 · Cited by 22
Lin, M., Sun, X. K., & Lv, L. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.04.007 · Cited by 22
“A study reported that genetic or pharmacological inhibition of VPS34 with SB02024 or SAR405 (VPS34i) could inhibit tumor growth by establishing a T cell-inflamed TME, improving the efficacy of anti-PD-L1/PD-1 blockade therapies.(165) Natural compounds have been applied for cancer treatment based on their tumor roles i…”
BackgroundTan, H., Liu, J., Huang, J., Li, Y., Xie, Q., Dong, Y., Mi, Z., Ma, X., & Rong, P. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04312-2 · Cited by 19
Hypoxia Induces Autophagy in Human Dendritic Cells: Involvement of Class III PI3K/Vps34
Monaci, S., Coppola, F., Rossi, D., Giuntini, G., Filippi, I., Marotta, G., Sozzani, S., Carraro, F., & Naldini, A. (2022) · Cells · doi:10.3390/cells11101695 · Cited by 20
“This could also be particularly relevant in cancer treatment, as it has been recently reported that inhibition of Vps34 reprograms cold into hot inflamed tumors, thus, improving anti-PD-1/PD-L1 immunotherapy in melanoma and colorectal cancer mouse models [59].”
BackgroundThe Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
Janji, B., & Chouaïb, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880810 · Cited by 19
Self-citationGao, Y., Peng, Q., Li, S., Zheng, K., Gong, Y., Xue, Y., Liu, Y., Lu, J., Zhang, Y., & Shi, X. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113486 · Cited by 20
Hu, J., Fu, S., Zhan, Z., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116109 · Cited by 20
Oyama, K., Nakata, K., Tsutsumi, C., Hayashi, M., Zhang, B., Mochida, Y., Shinkawa, T., Hirotaka, K., Zhong, P., Date, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0830 · Cited by 20
“Although several studies have already shown that autophagy in cancer cells can be therapeutically targeted to enhance antitumor immunity (22, 24, 48), we are the first to demonstrate that the inhibition of cancer cell autophagy triggered DC activation by increasing the accumulation of antigens.”
Zhou, F., Li, X., Xue, X., Li, S., Fan, G., Cai, Y., Chang, Z., Qu, J., & Liu, R. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202757 · Cited by 18
Vps34 sustains Treg cell survival and function via regulating intracellular redox homeostasis
Feng, P., Yang, Q., Luo, L., Guan, Z., Fu, J., Zhao, M., Meng, W., Wan, S., He, J., Li, Z., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01353-y · Cited by 19
Noman, M. Z., Bocci, I. A., Karam, M., Moer, K. V., Bosseler, M., Kumar, A., Berchem, G., Auclair, C., & Janji, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980704 · Cited by 15
Self-citationLiu, Y., Lu, R., Li, M., Cheng, D., Wang, F., Ouyang, X., Zhang, Y., Zhang, Q., Li, J., & Peng, S. (2024) · Materials Horizons · doi:10.1039/d3mh01844j · Cited by 16
Regulatory Mechanisms Governing the Autophagy-Initiating VPS34 Complex and Its inhibitors
Lee, Y., Nguyen, T. M., Lee, G. J., Kim, B., Park, J., & Lee, C. H. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.094 · Cited by 17
“Consequently, numerous studies are underway targeting VPS34 as a potential therapeutic target (Pasquier, 2015; Robke et al ., 2017; Noman et al ., 2020; Murali et al ., 2021; Liu et al ., 2023).”
BackgroundShi, C., Fu, W., Zhang, X., Zhang, Q., Zeng, F., Nijiati, S., Du, C., Liu, X., Wang, M., Yao, Y., et al. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200163 · Cited by 16
Truong, T., Webber, K. G. I., Johnston, S. M., Boekweg, H., Lindgren, C. M., Liang, Y., Nydegger, A., Xie, X., Tsang, T., Jayatunge, D., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202303415 · Cited by 17
Yu, Y., Jagannathan‐Bogdan, M., Noman, M. Z., Parpal, S., Bartolini, E., Moer, K. V., Kleinendorst, S. C., Sæther, K. B., Tresaugues, L., Silvander, C., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13619 · Cited by 15
“We previously demonstrated that VPS34 inhibition reduces tumor growth in murine cancer models of melanoma, CRC, and renal cell carcinoma (RCC) [18].”
BackgroundMethodResultInfluentialSelf-citationNew horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review)
Bhaliya, K., Anwer, M., Munn, A. L., & Wei, M. Q. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2799 · Cited by 13
“…that polydopamine‑based PDA‑PEG‑R848‑CD nanoparticles impacted 4T1 breast tumors under NIR laser irra‑ diation, generated tumor‑associated antigens and significantly improved the efficacy of PD‑L1 checkpoint blockade therapy, activating innate and adaptive immune systems in vivo (36,37).”
Hu, Y., Yu, Q., Li, X., Wang, J., Guo, L., Huang, L., & Gao, W. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403493 · Cited by 14
Aging, cancer, and autophagy: connections and therapeutic perspectives
Zapatería, B., & Arias, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1516789 · Cited by 16
Targeting autophagy drug discovery: Targets, indications and development trends
Jiang, M., Wu, W., Xiong, Z., Ye, Z., Ye, Z., & Wu, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116117 · Cited by 15
Role of Tumor Cell Intrinsic and Host Autophagy in Cancer
Guo, J. Y., & White, E. P. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041539 · Cited by 14
Application of Liposome-Based Drug Delivery Systems in Tumor Treatment
Sun, W., & He, W. (2025) · Journal of Cluster Science · doi:10.1007/s10876-025-02836-9 · Cited by 12
“The results demonstrated that DOX-SAR-JY4LIPO signifi - cantly inhibits tumor growth, metastasis, and recurrence by reshaping the immunosuppressive tumor microenvironment [58].”
Enhancing anti-tumor immunity by autophagy inhibition
Thorburn, A. M., & Towers, C. G. (2021) · Nature Cancer · doi:10.1038/s43018-021-00214-8 · Cited by 14
Li, L., Wang, X., Jiang, M., Li, L., Wang, D., & Li, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117420 · Cited by 11
Pedrosa, L., Foguet, C., Oliveres, H., Archilla, I., de Herreros, M. G., Rodríguez, A., Postigo, A. A., Benítez‐Ribas, D., Camps, J., Cuatrecasas, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.926304 · Cited by 13
“We hypothesize that autophagy inhibitors such as chloroquine (27) or selective autophagy target inhibitors (38) such as metformin (a citrate transport and gluconeogenesis inhibitor) (39, 40), or CCS1477 (an inhibitor of p300/CBP) currently in clinical development (41, 42), can increase ICI efficacy in this cluster.”
BackgroundYeo, S. K., Haas, M., Manupati, K., Hao, M., Yang, F., Chen, S., & Guan, J. (2023) · Autophagy · doi:10.1080/15548627.2023.2259775 · Cited by 11
“To overcome this problem, there is a need to identify strategies that can stimulate immuno-logically quiescent or “cold” tumors into immunologically “hot” tumors, with increased tumor infiltrating lymphocytes (TILs) and improved responses to ICIs [5,7].”
BackgroundNguyen, T. H., Nguyen, T. M., Ngoc, D. T. M., You, T., Park, M. K., & Lee, C. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216255 · Cited by 11
Lope, A. L., Loughran, R. M., & Emerling, B. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1297355 · Cited by 10
Yamamoto, K., Iwadate, D., Naito, E., Tateishi, K., & Fujishiro, M. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103012 · Cited by 12
Wu, N., Zhang, Q., Tang, R., Deng, L., Cao, Y., Fu, B., Dong, H., Huang, Z., Wan, L., He, H., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c03394 · Cited by 11
Jiao, Y., & Xiang, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1595463 · Cited by 13
Jalouli, M., Harrath, A. H., Al-Zharani, M., & Rahman, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052183 · Cited by 12
Autophagy modulation in cancer
Guilbaud, E., Ryan, K. M., Green, D. R., & Galluzzi, L. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01449-9 · Cited by 13
“247,248) or more specific agents with autophagy-inhibiting activity 243 .”
Berquez, M., Li, A. L., Luy, M., Venida, A. C., McDowall, S., O'loughlin, T., Rademaker, G., Barpanda, A., Hu, J., Yano, J., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.05.005 · Cited by 12
Recent advances of vacuolar protein-sorting 34 inhibitors targeting autophagy
Chen, L., Gao, T., Zhou, P., Xia, W., Yao, H., Xu, S., & Xu, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107039 · Cited by 12
Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies
Xiong, J., & Wang, Q. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.07.006 · Cited by 11
Webber, K. G. I., Huang, S., Lin, H. L., Hunter, T. L., Tsang, J., Jayatunge, D., Andersen, J. L., & Kelly, R. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100880 · Cited by 11
Li, S., Wang, S., & Zou, X. (2022) · Computers & Mathematics with Applications · doi:10.1016/j.camwa.2022.03.012 · Cited by 9
Zhou, F., Li, X., Jia, K., Li, F., Xue, X., Liu, J., Qu, J., & Liu, R. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106581 · Cited by 9
Sun, C., Zhan, J., Li, Y., Zhou, C., Huang, S., Zhu, X., & Huang, K. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18348 · Cited by 9
“186 It has been reported that high doses of IL-2 can cause systemic autophagy syndrome with increased levels of IFN-γ , IL-6 and IL-18 expression.”
BackgroundImproving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34
Bartolini, E., Moer, K. V., & Janji, B. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2364958 · Cited by 9
Self-citationALKhemeiri, N., Eljack, S., & Saber-Ayad, M. M. (2025) · Cells · doi:10.3390/cells14100745 · Cited by 11
From Intestinal Epithelial Homeostasis to Colorectal Cancer: Autophagy Regulation in Cellular Stress
Liu, Q.-L., Chen, Y., Zhou, L., Chen, H., & Zhou, Z. (2022) · Antioxidants · doi:10.3390/antiox11071308 · Cited by 11
Zhu, Z., Zhao, Q., Li, S., Weng, J., Guo, T., Zhu, C., & Xu, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.984743 · Cited by 9
“Tumors have been classified into “hot tumor” and “cold tumor” according to the immune cell infiltration around tumors, and further regrouped into three types: immune-inflamed, immune-excluded and immune-desert (Galon and Bruni, 2019; Noman et al., 2020; Bruchard et al., 2022; Eggermont et al., 2022).”
BackgroundCancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation
Zhang, G., Chen, Y., Huang, X., & Liang, T. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.001 · Cited by 9
Neutrophil Engulfment in Cancer: Friend or Foe?
Lu, T., & Li, W. (2025) · Cancers · doi:10.3390/cancers17030384 · Cited by 9
“VPS34 inhibition promoted the release of the pro-inflammatory chemokines CXCL10 and CCL5 via STAT1/IRF7 induction within tumors [153].”
InfluentialZhang, H., Yu, X., Yang, J., He, G., Zhang, X., Wu, X., Li, S., Zhou, Y., Cheng, X., Liu, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933779 · Cited by 10
“Vps34 kinase inhibitor (Vps34i) can induce a T cellinflamed tumor microenvironment construction (including infiltration of NK, CD8+, and CD4+ T effector cells) featured by high amplification of CCL5, CXCL10, and IFN-g, thereby converting immune cold tumors (poorly infiltrated) into hot ones (highly infiltrated) (46).”
BackgroundThe role of chaperone-mediated autophagy in drug resistance
Teixeira, A. B. D. S., Ramalho, M. C. C., de Souza, I., de Andrade, I. A. M., Osawa, I. Y. A., Guedes, C. B., de Oliveira, B. S., Filho, C. H. D. D. S., da Silva, T. L., Moreno, N. C., et al. (2024) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2023-0317 · Cited by 10
“Given the substantial data regarding the role of autophagy in supporting tumor growth and promote resistance (Levy et al ., 2017; Mele et al ., 2020; Noman et al ., 2020), researchers are actively investigating how to modulate it to enhance and overcome antitumor treatments, with promising results…”
BackgroundEx vivo anchored PD‐L1 functionally prevent in vivo renal allograft rejection
Luo, Z., Liao, T., Zhang, Y., Zheng, H., Sun, Q., Han, F., Ma, M., Ye, Y., & Sun, Q. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10316 · Cited by 8
“Programmed cell death protein-1 (PD-1) and its ligand PD-L1 are important immune checkpoint molecules that negatively regulate the immune system.(7,8) It has been reported that PD-L1 represses rejec-”
BackgroundNie, Y., Yao, G., Li, L., Feng, A., Zhang, W., Xu, X., Li, Q., & Yang, Z. (2022) · Cancer Management and Research · doi:10.2147/cmar.s375821 · Cited by 9
“Although these agents have been associated with significantly prolonged OS in patients with esophageal cancer, only a small proportion of patients can benefit from ICIs alone.(9,10) Studies are needed to determine whether combinations of immunotherapy with and other types of treatment can prolong survival in patients…”
BackgroundYang, H., Li, M., Deng, Y., Wen, H., Luo, M., & Zhang, W. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23233 · Cited by 7
“25 Moreover, oncolytic viruses have shown great potential in pediatric tumor therapy.”
BackgroundTumor-intrinsic redox programming drives an SPP1-CD44 axis of immune suppression in uveal melanoma
Ge, T., Yang, Y., Zhang, W., Li, M., Gu, X., Yang, L., Jia, R., Wang, X., Fan, X., & Zhuang, A. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104011 · Cited by 7
“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
Janji, B., & Chouaı̈b, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1968611 · Cited by 6
Self-citationLiu, Y.-T., Cai, H.-R., He, L., Mu, Q., Huang, J.-Y., & Gao, Y. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120317 · Cited by 5
Targeting autophagy in dysfunctional tumor vasculature
Lin, Q., Cai, B., Ke, R., Ni, X., Wan, X., Chen, L., Huang, T., Shan, X., & Wang, B. (2025) · iScience · doi:10.1016/j.isci.2025.114084 · Cited by 6
The regulatory role of autophagy between TAMs and tumor cells
Hu, M., Fan, J., He, Z., & Zeng, J. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3984 · Cited by 6
“…by major mechanisms including impaired antigen presentation, 105,106 inhibition of infiltration of antitumor immune cells such as T ‐ lymphocytes 107,108 and targeting of tumor ‐ associated immune regulatory cells to immunogenic cells that promote tumor rejection, 109 leading to antitumor…”
BackgroundPIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation
Sanchez, S., McDowell-Sanchez, A. K., Al-Meerani, S. B., Cala-García, J., Waich, A., Ochsner, S. A., McKenna, N. J., Celada, L. J., Wu, M., Assassi, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306624 · Cited by 4
Cell death in bryophytes: emerging models to study core regulatory modules and conserved pathways
Marchetti, F., Distéfano, A. M., Cainzos, M., Setzes, N., Cascallares, M. M., López, G. A., Zabaleta, E. J., & Pagnussat, G. C. (2024) · Annals of Botany · doi:10.1093/aob/mcae081 · Cited by 4
Therapeutic Targeting of Autophagy in Pancreatic Cancer
Foth, M., Garrido‐Laguna, I., & Kinsey, C. G. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.001 · Cited by 4
Caux, M., Chicanne, G., & Séverin, S. (2022) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-06566-8_3 · Cited by 6
Fan, L., Wei, Z., Liu, L., Qi, X., & Yu, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1220435 · Cited by 4
Liang, L., Guo, P., Xiao, M., Zu, F., Hao, G., Zhang, C., & Liu, Q. (2025) · Discover Oncology · doi:10.1007/s12672-025-03061-6 · Cited by 3
“In recent years, studies on PIK3C3, MAGEA6 and MHC-1 have shown that combined immuno-therapy has important research value in inhibiting pancreatic cancer [18–20].”
Self-citationPI3K/mTOR Inhibitor Induces Context-Dependent Apoptosis and Methuosis in Cancer Cells
Hua, X., Chen, P., Zeng, W., Han, Y., Guo, Y., Chen, Y., Li, C., Du, Y., Ma, M., & Dong, S. (2025) · Pharmaceuticals · doi:10.3390/ph18121849 · Cited by 3
“Thus, Our VPS34 inhibitor YYN-37 holds promise for broader therapeutic applications and warrants further investigation.”
Wu, H., Huang, W., Cai, X., He, H., Wang, Y., Yao, S., Zhu, L., Wang, Z., Sun, Y., Liu, Y., et al. (2026) · Lasers in Surgery and Medicine · doi:10.1002/lsm.70103 · Cited by 4
“Proinflammatory: IRF7: IL‐6 [31, 43–47]; IL‐1β [32, 44, 48–51]; TNF‐α [43, 44]; iNOS [32, 52, 53]; NLRP3 [32, 44, 48]; NF‐κB [53–55]; IL‐5 [56]; IL‐13 [56]; IL‐23 [57]; CCL2 [43]; CCL5 [54, 58]; CXCL2; CXCL10 [54, 58, 59]; IL‐10, Arg1 [32, 53]; CD86 (for M1 macrophage) [32, 44, 52, 53, 60].”
Noman, M. Z., Szpakowska, M., Xiao, M., Gao, R., Moer, K. V., Kumar, A., Ollert, M. W., Berchem, G., Chevigné, A., & Janji, B. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2494426 · Cited by 3
“However, the expression CCL5 and CXCL10 can be enhanced through various strategies 13,16,17 Using two different siRNA sequences targeting Ackr2 , we observed a significant increase in the release of CCL5 and CXCL10 in Ackr2 -knockdown cells compared to controls (Figure 1(a)).”
Self-citationBai, J., Wang, M., Luo, Y., Duan, B., Yang, Y., Fu, Y., Li, S., Yang, Z., Zheng, P., Yu, T., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03471-2 · Cited by 4
“Conversely, the B16-F10 melanoma cell line is widely recognized as an "immune cold" tumor model, attributed to its low immunogenicity and potent immune suppression mechanisms [43].”
Sharma, N. D., Keewan, E. F., Ornatowski, W., Paul, S., Nysus, M. V., Barnett, C. C., Wolfson, J. A., Jacquez, Q., Myers, B. L., Kang, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188888 · Cited by 3
Yan, Z., Chu, S., Zhu, C., Han, Y., Liang, Q., Shen, S., Cheng, W., & Wu, A. (2021) · PeerJ · doi:10.7717/peerj.12547 · Cited by 4
“A number of recent studies (Tumeh et al., 2014; Du et al., 2020; Noman et al., 2020) showed that compared with cold tumors, hot tumors have increased sensitivity to immunotherapy, thus allowing for more immunotherapy opportunities.”
Background
Metadata
- Authors
- Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., Amaravadi, R. K., Martinsson, J., Berchem, G., & Janji, B.
- Affiliations
- Luxembourg Institute of Health (LU)
- Karolinska Institutet (SE)
- Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
- Sprint Bioscience (Sweden) (SE)
- Sprint Bioscience, Stockholm, Sweden.
- Abramson Cancer Center (US)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Berchem, Guy
- Janji, Bassam
- ORCID
- Venue
- Science Advances
- Published
- 2020-05
- Volume
- 6
- Issue
- 18
- Pages
- eaax7881-eaax7881
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7190323
- OpenAlex
- W3021675475
- Cited by
- 255
- References
- 40
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 51 · 2023: 46 · 2022: 55 · 2021: 39 · 2020: 15
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Luxembourg National Research Fund (C18/BM/12670304/COMBATIC)
- FNRS Televie (7.4664.15; 7.6503.16; 7.4606.18)
- Fondation Cancer, Luxembourg (FC/2016/01 and FC/2018/06)
- Kriibskrank Kanner Foundation Luxembourg (2016-08-15)
- Janssen Cilag Pharma
- Action LIONS Vaincre le Cancer, Luxembourg
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- tumor immune microenvironment, PD-1/PD-L1 blockade, melanoma, colorectal cancer, T cell infiltration, RANTES, CXCL10, interferon-gamma, STAT1, IRF7, inflammatory chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.